Cuprina Holdings (Cayman) Stock Price, News & Analysis

Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) is a Singapore-based biomedical and biotechnology company focused on the development and commercialization of products for the management of chronic wounds, infertility and cosmeceuticals in the health and beauty sector. Across its activities, the company emphasizes the use of materials derived from natural sources to develop wound care products in the form of medical devices that meet international standards.

According to multiple company disclosures, Cuprina positions itself as a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling and cosmeceuticals sectors. Its core expertise in biomedical research underpins a portfolio that includes chronic wound therapies, infertility-related products, health and beauty applications, and technology for medical waste recycling.

Chronic wound management and MEDIFLY maggot debridement therapy

Cuprina has developed and marketed MEDIFLY maggot debridement therapy (MDT) products for chronic wound treatment. These products use medical-grade sterile blowfly larvae as a biological debridement tool for chronic wounds, offering an alternative to surgical debridement. Company news reports describe MEDIFLY as part of Cuprina’s core chronic wound business and note efforts to expand its reach into new clinical markets, particularly in the Middle East and North Africa (MENA) region.

Through its indirect 49%-owned associate Cuprina MENA Co. Ltd, the company has completed the set-up of a laboratory in Saudi Arabia equipped to manufacture MEDIFLY MDT products and supply them across the MENA region. Cuprina MENA is working toward regulatory approvals, including Saudi Food and Drug Authority registration and ISO 13485 certification, to enable commercial distribution of these chronic wound therapies in the region.

Biotherapeutics and medical maggots, leeches and related therapies

Cuprina’s chronic wound activities extend to broader biotherapeutic approaches. The company has secured a licensing agreement for an FDA-cleared medical maggot product, Lucilia sericata Medical Maggots™, giving it rights to manufacture, sell, use and distribute these maggots and associated dressings for MDT in the United States. The company has also disclosed that it is updating its own FDA submission for another species of medical maggots, Lucilia cuprina, as part of its MDT-related regulatory strategy.

In addition, Cuprina’s MENA associate has obtained exclusive rights from Biopharm UK Ltd to sell medicinal leeches across the Gulf Cooperation Council (GCC) countries. Company communications describe medicinal leeches as being used in the GCC to address conditions such as venous congestion, to support tissue healing and circulation after reconstructive and microsurgery procedures, to relieve symptoms of osteoarthritis, and in veterinary surgery applications.

Infertility and IVF media production

Cuprina also operates in the infertility sector. The company reports that it has completed construction of an in-vitro fertilization (IVF) media production facility in Singapore and obtained ISO 13485 certification and a dealer license for this facility. The IVF media product is described as containing nutrients, electrolytes, amino acids and other materials required to stimulate fertilization of sperm and ovum in the laboratory. The company has stated its intention to seek regulatory approval from Singapore authorities to commence commercial sales of this IVF media.

Medical waste recycling technology

Beyond direct patient therapies, Cuprina is active in medical waste recycling. It has secured exclusive licensing rights to a medical waste recycling technology developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF). The license covers Singapore and includes an option to expand into additional Southeast Asian countries.

Company disclosures explain that this technology uses a high-temperature steam process (autoclaving) to sterilize and decontaminate medical waste, particularly plastic-based materials. Once treated, the materials can be sorted and recycled into high-value resins and converted into sustainable raw materials that re-enter the economy. Cuprina has described plans to apply for operating licenses in Singapore to construct a facility for this technology and has signed a Memorandum of Understanding with Singapore Biowaste Solutions Pte Ltd to explore integrating this recycling process into an existing waste management facility.

Health, beauty and cosmeceuticals

Cuprina operates in the health and beauty sector through cosmeceutical products. The company states that it leverages materials derived from natural sources to develop products that can be used in cosmetic and skin-related applications. It has reported research collaborations with institutes of higher learning in Singapore to generate collagen peptide molecules derived from American bullfrog skin, with potential cosmeceutical uses such as skin moisturization, collagen remodeling and other commercial applications. The company has indicated that it is pursuing marketing opportunities for these bullfrog collagen peptides with cosmeceutical entities.

Bullfrog collagen and research collaborations

Cuprina has highlighted several research collaborations focused on bullfrog-derived collagen peptides. These collaborations include consultancy and research agreements with Republic Polytechnic, the Institute for Health Innovation and Technology at the National University of Singapore, and the Singapore Institute of Technology. The work involves generating bullfrog collagen peptides that can be sold as is or separated into individual peptide fragments, exploring their use in 3D printable wound care dressings, and developing powdered forms suitable for cosmeceuticals.

Company reports note that in vivo and in vitro tests have demonstrated that bullfrog skins generate a triple helix collagen molecule with properties such as biocompatibility and thermal stability compared to other collagen sources. Published studies cited by the company have reported wound closure outcomes using bullfrog-derived collagen relative to bovine collagen.

Iodine-based wound care and antiseptic products

Cuprina has entered into a joint venture agreement with Aiodine Laboratory Pte Ltd to develop, test and market an iodine-based disinfectant solution. Initial applications identified by the company include an antiseptic wound care formulation, disinfectants and daily home-use antiseptics, with additional opportunities under evaluation in personal care, oral hygiene and veterinary applications. A study referenced by the company and published in a peer-reviewed journal evaluated this iodine-based solution in patients with chronic wounds and reported outcomes related to wound healing, infection reduction, inflammation and tissue repair.

Geographic base and regulatory status

Cuprina describes itself as a Singapore-based company, with its principal executive offices located in Singapore. Its ordinary shares trade on The Nasdaq Capital Market under the symbol CUPR. The company has disclosed receiving a Nasdaq notification letter regarding minimum bid price deficiency under Nasdaq Listing Rule 5550(a)(2), noting that this letter does not result in immediate delisting and that its shares continue to trade under the CUPR symbol. The company has stated that it is evaluating options to regain compliance with Nasdaq’s continued listing requirements.

Business focus and sector positioning

Across its disclosures, Cuprina consistently characterizes itself as a biomedical and biotechnology company dedicated to chronic wound management, infertility-related products, cosmeceuticals and medical waste recycling. Its activities span medical devices for wound care, biotherapeutic modalities such as maggot and leech therapies, IVF media production, collagen-based research and environmental technologies for handling medical waste. The company emphasizes the use of natural-source materials and adherence to international standards in its wound care devices.